Clinical Infectious Diseases · Randomized Controlled Trial · 2024-03-11
Strong EvidenceLinezolid versus tedizolid for acute bacterial skin and skin-structure infections: a randomized noninferiority trial
Why it matters. Directly informs oxazolidinone selection and stewardship-driven duration decisions you may oversee.
Study design
- Design
- Multicenter, double-blind, randomized noninferiority trial
- Population
- Adults with acute bacterial skin and skin-structure infections
- Setting
- Multinational
- Sample size
- n = 720
- Intervention
- Tedizolid 200 mg daily x6 days
- Comparator
- Linezolid 600 mg twice daily x10 days
Provenance
- Source
- Clinical Infectious Diseases
- Source type
- peer_reviewed
- Content analyzed
- abstract
Evidence grading reflects the portion of the source actually analyzed. Always confirm against the original before acting.
Your read
Post your interpretation for colleagues. Every post stays anchored to this source, no empty-box updates.
Sign in to post your read of this evidence.